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Background: Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line gain of function mutations in
the RET proto-oncogene, and a phenotypic variability among carriers of the same mutation has been reported.
We recently observed this phenomenon in a large familial MTC (FMTC) family carrying the RET-S891A mutation.
Among genetic modifiers affecting RET-driven MTC, a role has been hypothesized for RET-G691S non-synonymous
polymorphism, though the issue remains controversial. Aim of this study was to define the in vitro contribution of
RET-G691S to the oncogenic potential of the RET-S891A, previously shown to harbour low transforming activity.
Methods: The RET-S891A and RET-G691S/S891A mutants were generated by site-directed mutagenesis, transiently
transfected in HEK293T cells and stably expressed in NIH3T3 cells. Their oncogenic potential was defined by
assessing the migration ability by wound healing assay and the anchorage-independent growth by soft agar
assay in NIH3T3 cells stably expressing either the single or the double mutants. Two RET-S891A families were
characterised for the presence of RET-G691S.
Results: The functional studies demonstrated that RET-G691S/S891A double mutant displays a higher oncogenic
potential than RET-S891A single mutant, assessed by focus formation and migration ability. Moreover, among the 25
RET-S891A carriers, a trend towards an earlier age of diagnosis was found in the MTC patients harboring RET-S891A in
association with RET-G691S.
Conclusions: We demonstrate that the RET-G691S non-synonymous polymorphism enhances in vitro the oncogenic
activity of RET-S891A. Moreover, an effect on the phenotype was observed in the RET-G691S/S891A patients, thus
suggesting that the analysis of this polymorphism could contribute to the decision on the more appropriate
clinical and follow-up management.
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Medullary Thyroid Cancer (MTC) is a neuroendocrine
neoplasia arising from thyroid parafollicular C cells. Her-
editary forms account for 25% of cases and include mul-
tiple endocrine neoplasia syndromes type 2A (MEN2A),
type 2B (MEN2B) and familial MTC (FMTC), caused by
mutations in the rearranged during transfection (RET)
proto-oncogene. The RET gene, which encodes a tyrosine
kinase receptor with a crucial role in development, com-
prises 21 exons and generates a transcript subjected to al-
ternative splicing leading to two main isoforms: a protein
of 1114 residues displaying 51 C-terminal-specific amino
acids (RET51) and a shorter protein of 1072 residues
displaying nine unrelated C-terminal-specific amino acids
(RET9) [1].
Beyond the known role of RET gain-of-function muta-
tions in MTC, in recent years several authors investigated
whether the presence of single nucleotide polymorphisms
(SNPs) could be associated with susceptibility for the
development or progression of MTC [2-5]. Among RET
polymorphisms, RET-G691S, localized in exon 11 and re-
ported in general population with an allele frequency of
11–33% (ARUP database “MEN2 and RET”, displaying se-
quence variation and clinical information [6]), is a non-
synonymous variant [7-9], and could potentially affect
protein function. Moreover, RET-G691S has been sug-
gested to be a genetic modifier in MEN2A, related to an
earlier age at presentation [7,9,10] and has been associated
to the susceptibility to sporadic MTC [8,11-13], though
controversial data have been reported about this issue [14].
Interestingly, RET-G691S has been also hypothesized
to play a functional role on tumor growth and aggressive-
ness in pancreatic cancers and cutaneous melanoma, where
it works as a genetic modifier or even as a low penetrance
gene [15,16]. In particular, RET-G691S was reported to en-
hance the activation of the downstream ERK pathway com-
pared to RET-wt [15], though this variant was not found
to be oncogenic per se by focus formation assays [5,17].
Consistently with the potential modifier role of RET-
G691S in MTC, Vandenbosch et al. observed that this
polymorphism is able to enhance RET oncogenicity of
mutations affecting RET codon 666, by increasing its
penetrance in the clinical onset [18]. Accordingly, we
firstly demonstrated the in vitro effect of the RET-G691S
variant as enhancer of the ERK1/2 activation and of the
transforming activity of the MTC-associated RET-K666E
mutant [17].
In the present study, we investigated more deeply the
potential role of this non synonymous RET polymorph-
ism as a modifier of the phenotypic expression in famil-
ial MTC. To this purpose, we focused on the potential
contribution of RET-G691S to the oncogenicity of RET-
S891A, a RET mutant previously reported to be associ-
ated with low transforming activity. In particular, thisgain-of-function mutation, located in the second intracel-
lular tyrosine kinase domain of the RET proto-oncogene,
accounts for less than 5% of all RET mutated patients,
and can cause FMTC or the phenotype associated to
MEN2A [19-23].
Since the functional characterization of RET mutants
adds useful information to the genotyping of patients/
families optimizing the diagnostic and clinical manage-
ment, we both evaluated the in vitro biological activity of
the RET-G691S polymorphism on the oncogenic poten-
tial of RET-S891A and carried out expression/penetrance
studies in two unrelated RET-S891A FMTC families.
Methods
In vitro analyses
Construction of the RET mutants
All RET mutants were obtained by mutagenesis of RET51-
wt construct (pCDNA3 vector expressing the proto-RET
gene long isoform). RET51-G691S, RET51-C634R (con-
taining an MEN2A causing mutation), and RET51-M918T
(containing the main MEN2B causing mutation) used as
controls are described elsewhere [17].
RET51-S891A and RET51-G691S/S891A were obtained
by site-directed mutagenesis of RET51-WT using an in vitro
oligonucleotide mutagenesis system (Quik-Change XL site-
directed mutagenesis; Stratagene, La Jolla, CA, USA). The
transition c.2071G > A leading to G691S polymorphism
(SNIP rs1799939) and the transversion c.2671 T >G lead-
ing to S891A mutation were verified by DNA direct
sequencing and then the mutant clones were entirely se-
quenced to exclude possible additional mutations. Plasmid
DNA was extracted using the MAXI PREP Kit (Qiagen)
as suggested by the supplier.
Cell culture, transfections and focus formation assay
Human HEK293T cells were maintained in DMEM with
10% FCS. The recombinant plasmids were transiently
transfected using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s instructions.
NIH3T3 cells were cultured in DMEM supplemented
with 10% serum (Colorado Company, CO). Stable trans-
fection was performed by the CaPO4 method [24] using
100 ng plasmid DNA together with 10 μg NIH3T3-derived
DNA carrier. Transfected cells were grown in DMEM with
10% serum and selected in the presence of G418 antibiotic
(650 μg/ml) to obtain G418-resistant colonies indicative of
transfection efficiency; transformed foci were obtained in
DMEM with 5% serum in the presence of chronic stimu-
lation with the RET ligand GDNF at a concentration of
10 ng/ml (AlomoneLabs, Jerusalem, Israel). Both G418-
resistant colonies and transformed foci were fixed and
counted to determine the transforming activity, calcu-
lated as foci number/colonies number ratio. NIH3T3 cell
lines stably expressing RET mutants were derived from
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NIH3T3 transfected cells and cultured in the presence of
chronic stimulation of GDNF (10 ng/ml).
Western blot analysis
Cells were lysed in ice-cold RIPA buffer (20 mM Tris
pH 7.4, 137 mM NaCl, 10% glycerol, 0.1% SDS, 0.5% so-
dium deoxycholate, 1% Triton X-100, 2 mM EDTA pH 8.0)
containing protease and phosphatase inhibitors.
Proteins were quantified using a modified Bradford
assay (Bio-Rad). Protein samples were boiled in NuPAGE
LDS sample buffer (Invitrogen), separated by NuPAGE
Novex Gels with the appropriate running buffer (Invitrogen),
then transferred onto nitrocellulose filters, and immuno-
blotted with the indicated antibodies. Anti-RET (C-20),
anti-RET (H300) and anti-phospho-RET are from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); anti-MAP
kinase (ERK1/2), anti-MAP kinase activated (pERK1/2),
anti-vinculin and anti-β-tubulin are from Sigma Aldrich
(Saint Louis, Missouri, USA).
Densitometric analyses were performed by the Quantity
One 4.6.6 software (Bio-Rad, Hercules, CA).
Wound healing assay
NIH3T3 cells stably expressing RET mutants were
seeded at 30000 cells/chamber in a culture insert (Ibidi
#80209) placed in 24-well plate and incubated over-
night. Inserts were then removed to generate a 500 μm
gap between cells. Following PBS wash and fresh
medium supplement, plates were placed in the Cell-IQ
SLF instrument (CM Technology Oy, Tampere, Finland)
and cultured at 37°C, 5% CO2. Two images for well were
taken each hour for 24 h using Cell-IQ Imagen software
(CM Technology Oy) to monitor the gap closure.
Images were then analyzed with the Scratch wound
measurement tool of the Cell-IQ Analyser software
(CM Technology Oy), to evaluate the % of closed area
calculated with the equation: (Start wound - wound
[μm2])/Start wound × 100. Data and graphs were
analyzed using GraphPad Prism 5.02.
Soft-agar assay
For anchorage-independent growth assay, NIH3T3 cells
stably expressing RET mutants were suspended in DMEM
containing 0.33% agar, 10% serum and GDFN 10 ng/ml
(50000 cells/1.5 ml medium) and added into a layer of
medium containing 0.5% agar and 10% serum in 60 mm
dishes. After 3 weeks incubation, plates were analyzed for
colonies number and size. Colony number was determined
in plates stained with p-iodonitrotetrazolium chloride violet
(Sigma Aldrich).
Agar colonies size, calculated as mean diameter, was
determined by the count/size tool in Image-Pro Plus
7.0.1 software analyzing the agar colonies images the daybefore staining. A cutoff area of 250 pixel was manually
set on NIH3T3 control cells. Only foci surpassing the
cut-off area were automatically selected and scored by
the software. Diameter data relative to the total foci ana-
lyzed per each field were exported and the mean diam-
eter for each sample was calculated.
Patients: clinical and molecular characterization
RET-G691S polymorphism expression/penetrance was
assessed in two FMTC families carrying the germline
activating mutation RET-S891A. Family 1 is an extremely
large family with members distributed in several cities of
the North of Italy, with a common ancestor [25]. Data
related to some members of Family 1 have been partially
reported in a previous study [23]. Family 2, from Southern
Italy, is composed by 2 generations for a total of 3 subjects.
Clinical and molecular features, including age at diagnosis,
gender, TNM staging [26] and the disease’s outcome after
a mean follow-up time of 60 months were obtained for
both families. Patients were diagnosed and treated accord-
ing to the American guidelines for the management of
MTC [27,28]; in particular, RET gene carriers were
screened by means of yearly basal and stimulated CT
measurement and neck ultrasound. Prophylactic surgery
was performed at the first evidence of a positive provoca-
tive test.
Genomic DNA was extracted from peripheral blood
leucocytes of FMTC families members and the presence
of RET-G691S polymorphism was assessed by PCR and
direct sequencing as previously described [23]. All pa-
tients gave their informed consent, approved by the local
Ethical Committee, to the genetic characterization and
to the analysis of data.
Statistical analysis
Statistical analysis and graphs were generated using
GraphPad Prism version 5.02. Comparisons between two
groups were performed by two-tailed Student’s t-test
with unequal variance. A value of P < 0.05 was consid-
ered statistically significant.
Results
Transforming activity of RET-S891A and RET-G691S/S891A
mutants
To assess the contribution of the RET-G691S polymorph-
ism to the in vitro oncogenic potential of RET-S891A mu-
tant, both localized in the intracellular domains of RET
protein (Figure 1A), we generated RET-S891A single and
RET-G691S/S891A double mutants by site-directed muta-
genesis of recombinant plasmids carrying the RET-wt long
isoform.
The obtained mutants, the control mutants (MEN2A-
associated RET-C634R, MEN2B-associated RET-M918T,
RET-wt and RET-G691S) and the empty vector were
Figure 1 RET-S891A and RET-G691S/S891A mutants biochemical characterization and transforming activity. A. RET protein domains (CL,
cadherin-like; CR, Cysteine-rich; TM, transmembrane; JM, juxtamembrane; TK, tyrosine kinase) and the RET51 isoform C-terminal tail are indicated.
B. Western blot analysis of RET protein and associated ERK signaling in HEK293T cells transiently transfected. RET was detected by the antibody
RET H300, specific for the RET extracellular portion, and by RET C20, specific for the intracellular portion of the RET long isoform. Vinculin is shown
as protein loading control. Protein levels were quantified by densitometric analysis by Quantity One 4.6.6 software. Data are shown as mean
expression value ± SD for 2 independent transfections. C. RET-S891A and RET-G691S/S891A mutants transforming activity by focus formation assay
in NIH3T3 cells. pCDNA3 empty vector (Mock) and RET-M918T are included as negative and positive controls, respectively. The transforming
activity, calculated as foci number/colonies number ratio, is reported as mean ± SD of triplicate counts. Data from one representative of two
independent transfections are shown. D. Representative images of foci-derived clones. Scale bar 50um. E. Western blot analysis of RET protein
and associated ERK signaling in NIH3T3 cells stably expressing the indicated RET variants: 634, RET-C634R; 918, RET-M918T; 691/891, RET-G691S/
S891A; 891, RET-S891A. NIH, NIH3T3 untransfected cells. The partially and fully glycosylated forms of RET are identified in NIH3T3 cells. Vinculin is
shown as protein loading control. Three RET-G691S/S891A clones and four RET-S891A clones were analysed. The ratio pERK/ERK/RET was
calculated for each clone and the mean among clones ± SD was reported.
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proteins and the associated downstream signaling on
ERK1/2 were analyzed (Figure 1B). Although slightly
heterogeneous, all the constructs express detectable levels
of RET protein. Interestingly, the RET-G691S/S891A
double mutant appears to activate ERK1/2 pathway more
than the RET-S891A single mutant, as suggested by densi-
tometric quantification (Figure 1B, lower panel).
Then, in order to analyze the biological activity of both
mutants, we performed focus formation assay. The RET-
S891A single and RET-G691S/S891A double mutants,
the empty vector (negative control) and RET-M918T
mutant (positive control), were stably transfected in
NIH3T3 cells and the transforming activity was assessed
(Figure 1C).
The RET-S891A single mutant shows transforming activ-
ity lower than the well known RET-M918T mutant, con-
firming previous report that indicates RET-S891A mutationassociated to low transforming activity [21]. Interestingly,
RET-G691S/S891A double mutant displays a threefold
higher transforming activity than RET-S891A single mu-
tant (0.09 vs. 0.03 respectively), suggesting for this
polymorphism a role of transforming potential enhancer.
This is also suggested by the cells morphology (Figure 1D).
Indeed, whereas RET-S891A-derived cells display an
apparently more flat morphology, RET-G691S/S891A-
derived cells show a spindle shape morphology with con-
tact inhibition loss, more similar to RET-M918T-derived
control cells.
Western blot analyses performed on stable clones de-
rived from transfection foci show that cells expressing
the RET-G691S/S891A double mutant display on aver-
age higher levels of ERK1/2 phosphorylation, indicative
of ERK1/2 pathway activation, than RET-S891A single
mutant (Figure 1E), similarly to what shown in transient
transfections (Figure 1B, lower panel).
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display different migratory and anchorage-independent
growth abilities
To better characterize the tumorigenic properties of RET-
S891A single and RET-G691S/S891A double mutants,
we performed the wound healing assay (Figure 2). The
wound closure capacity, indicative of migration ability, was
assessed for both mutants in two representative clones ex-
pressing different levels of RET protein (Figure 2A). DataFigure 2 RET-S891A and RET-G691S/S891A stable mutants migration abi
associated ERK signaling in NIH3T3 cells stably expressing either RET-S891A or R
shown as protein loading control. Two clones expressing different levels of RET
cells are included as negative and positive controls, respectively. B. Woun
was quantified each hour for 24 h post-wound. Graphs are mean of two in
percentage at 12 h post-wound. Data are shown as mean ± SD of two ind
determined by Two-tailed Unpaired t test. *p < 0.05. D. Representative imaindicate that RET-S891A single mutants display a statisti-
cally significant reduced capacity to close the wound com-
pared with the RET-G691S/S891A double mutants. Of
note, the presence of the 691S variant enhances the wound
closure ability in clones expressing both high levels of RET
(691/891 clone 3 vs. 891 clone 5) and low levels of RET
(691/891 clone 1 vs. 891 clone 4).
Moreover, the anchorage-independent growth ability
was assessed by soft agar assay in cells expressing thelity by wound healing assay. A. Western blot analysis of RET protein and
ET-G691S/S891A. RET was detected by RET C20 primary antibody. Tubulin is
were analyzed for both variants. NIH3T3 cells and RET-M918T-expressing
d-healing assay in RET stable mutants. The wound closure percentage
dependent experiments performed in duplicate. C. Wound closure
ependent experiments performed in duplicate. Statistical significance
ges at 0 h and 12 h post-wound (x10).
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G691S/S891A double mutants give rise to a statistically
significant higher number of agar colonies than RET-
S891A single mutants (Figure 3A). In addition, the size
of agar colonies originated by RET-G691S/S891A double
mutants results statistically significant higher than those
generated by RET-S891A single mutants (Figure 3B). ToFigure 3 RET-S891A and RET-G691S/S891A stable mutants
anchorage-independent growth ability by soft-agar assay. A. Agar
colonies in NIH3T3 cells stably expressing either RET-S891A or
RET-G691S/S891A. NIH3T3 cells and RET-M918T-expressing cells
are included as negative and positive controls. The mean ± SD of
duplicate counts is reported. For RET-S891A and RET-G691S/S891A
mutants two independent clones were analyzed and the mean
between clones is reported. Data from one representative of two
independent soft-agar assays are shown. Below representative images
of the plates scored for agar colonies number and the corresponding
pictures of agar colonies the day before fixing and staining
(scale bar 200 um). B. Agar colonies mean diameter determined
by Image-Pro Plus 7.0.1 software. Data are presented as mean
diameter ± SD for each sample. For RET-S891A and RET-G691S/S891A
two independent clones were analyzed and the mean between clones
is reported. ***P < 0.0001 statistical significance determined via Student’s
t-test. Below representative images of agar colonies used for diameter
measurement (LEICA inverted microscope, scale bar 1000 μm).be noted, RET-M918T mutant generates agar colonies big-
ger than RET-G691S/S891A double mutants in agreement
with its reported high oncogenic potential. These results
indicate that in RET mutants the presence of the G691S
polymorphism enhances the oncogenic properties, such as
the migration and the agar colony formation ability.
Allele frequency of RET-G691S polymorphism in FMTC
cases harboring RET-S891A mutation and correlation
between genetic and clinical features
The RET-S891A germline mutation was present in 39/69
members of the two FMTC families analyzed, whereas
the RET-G691S polymorphism was documented in 16/
69 cases (23.2%). Among the 39 RET-S891A carriers, 14
also harbored the RET-G691S polymorphism either in
heterozygosis (n = 13) or in homozygosis (n = 1), show-
ing an overall allele frequency of 19% (15 mutated alleles
out of 78 alleles). Thus, in the present series, the preva-
lence of the co-segregation RET891/RET691 was similar
to that reported in general population by the publicly
available ARUP database [6]. Interestingly, RET-G691S
appears to display a trans presentation with RET-S891A in
Family 1, whereas a cis presentation is observed in Family
2 (Table 1). In 25/39 RET-S891A carriers, the clinical re-
cords were available, and they were thus classified accord-
ing to the histologic diagnosis: 13 MTC, 6 CCH and 6 non
C-cells disease (Table 1).
Interestingly, even though not statistically significant, a
trend towards an earlier age at diagnosis was found in
MTC patients harboring the RET-G691S polymorphism
either considering MTC patients of Family 1 (median
age 30 vs. 46 years; Additional file 1: Figure S1A), or the
two families all together (median age 36.5 vs. 46 years;
Additional file 1: Figure S1B) thus confirming in vivo the
role of this polymorphism in the enhancement of the
oncogenic activity of RET-S891A. Consistently, 2/3 mem-
bers of Family 2 carrying RET-G691S/S891A had elevated
urinary normetanephrine levels (#VN 445.3 mcg/24 h,
nv <390 μg/24 h and #SV 578 mcg/24 h, nv <354 μg/24 h),
though no lesion suspicious for pheochromocytoma
(PHEO) have been yet identified using specific imaging
screening (CT scan, FDG PET and MIBG scintiscan). Fi-
nally, no significant differences were noted in the outcome
of patients with or without RET-G691S, likely as a conse-
quence of the bias introduced by prophylactic thyroidec-
tomy in gene carriers.
Discussion
In this study we demonstrated for the first time that the
functional polymorphic variant RET-G691S, not onco-
genic per se, enhances the in vitro oncogenic potential of
the RET-S891A, a mutant causing hereditary MTC. Fur-
thermore, we showed in two FMTC families that carriers
of RET-S891A mutation associated with the RET-G691S
Table 1 Features and 691 polymorphic status of patients harboring the RET-S891A germline mutation
Patient Gender Age at Dx (years) RET 691 691 variant Diagnosis TNM Stage
Family 1 6 TL M 15 G/G wt Normal - -
7 RA M 18 G/G wt Normal - -
1 BS M 5 G/S polymorphic Normal - -
2 RF M 7 G/S polymorphic Normal - -
4 RM M 9 G/S polymorphic Normal - -
10 RE F 27 G/S polymorphic Normal - -
3 TM M 8 G/G wt CCH - -
8 MM M 24 G/G wt CCH - -
21 RP M 56 G/G wt CCH - -
5 BM M 10 G/S polymorphic CCH - -
9 RL M 24 G/S polymorphic CCH - -
11 RI F 27 G/S polymorphic CCH - -
16 FE F 42 G/G wt MTC pT1N0M0 I
17 BA F 43 G/G wt MTC pT1N0M0 I
18 FA M 43 G/G wt MTC pT1N0M0 I
19 BC F 46 G/G wt MTC pT3N1bM0 IVA
20 MC F 54 G/G wt MTC pT2N1aM0 III
22 RU M 62 G/G wt MTC pT1NXM0 I
25 TG F 76 G/G wt MTC pT1N1aM0 III
12 RS F 29 G/S polymorphic MTC pT1NXM0 I
23 RL F 71 G/S polymorphic MTC pT2NXM0 II
13 RF M 30 G/S polymorphic MTC pT1N1aM0 I
Family 2 14 VV F 35 G/S polymorphic MTC pT1NXM0 I
15VN* M 38 G/S polymorphic MTC pT1NXM0 I
24 SV* F 74 S/S polymorphic† MTC pT2N1aM0 III
Age at Dx, age at diagnosis; G/G, Glycine/Glycine; G/S, Glycine/Serine; S/S, Serine/Serine; wt, wild type; Normal, absence of C-cells disease; CCH, C cells hyperplasia;
MTC, medullary thyroid cancer;
*elevated urinary normetanephrine levels.
†RET-G691S polymorphism in homozygosis.
The Table includes the 25 patients for whom clinical data are available.
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at diagnosis of MTC and the adrenal medulla involvement.
RET mutations in hereditary MTC are a paradigmatic
example of clinical decision based on molecular diagno-
sis. Nevertheless, even within families and patients with
the same RET mutation, the age of disease onset and the
phenotypes are unpredictable, suggesting the existence
of modifier loci influencing the expression and severity
of the disease whose identification could drive the diag-
nostic and therapeutic management. Accordingly, though
RET-S891A mutation has been associated to isolated
FMTC for several years after its first identification in 1997
[29], a MEN2 clinical spectrum has been more recently
reported in around 4% of cases [19]. Interestingly, a recent
case report paper identify bilateral pheochromocytoma as
the first manifestation of MEN2A disease in a patient of a
family carrying the RET-S891A mutation [30].Among the potential genetic modifiers, RET gene poly-
morphisms have been associated with susceptibility and/
or disease progression [2-5], and the attention has been
mainly focused on the non-synonymous variant RET-
G691S. Although debated, RET-G691S has been suggested
to have a role in MTC susceptibility and in the modulation
of the age of onset [7-9,13,31]. In this context we recently
showed that RET-G691S, not oncogenic per se, enhances
in vitro the oncogenic potential of the rare germline muta-
tion RET-K666E [5,17], accordingly with the observation of
Vandenbosch et al. that this polymorphism is able to in-
crease the penetrance in the clinical onset of mutations af-
fecting RET 666 codon [18].
In the present work, to get more insights and to confirm
the possible role of RET-G691S in the modulation of the
oncogenic capacity and phenotype expression of RET mu-
tants, we focused on the RET-S891A. This intermediated
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[21] that may be enhanced by GDNF treatment (data not
shown), as previously reported for other RET mutations lo-
calized in the tyrosine kinase domain, such as RET-M918T
causally related to MEN2B [32]. In agreement with our
initial hypothesis, we showed in this study that also for
RET-S891A mutation the association with RET-G691S
polymorphism correlates in vitro with enhanced tumori-
genic properties such as transforming activity and migra-
tory and clonogenic ability. These findings, indicating a
possible role of genetic modifier for this polymorphism,
are concordant with the expression/penetrance pattern of
the two analyzed RET-S891A FMTC families, that include
members harboring the RET-S891A mutation associated
or not with the RET-G691S polymorphism. Though not
statistically significant, an earlier age at diagnosis of MTC
was observed in RET-G691S/S891A carriers compared
with RET-S891A carriers, suggesting a possible role in the
modulation of the age at disease onset.
Our in vitro studies, mimicking the cis presentation of
RET-S891A mutation and RET-G691S polymorphism
observed in the Family 2, demonstrate the oncogenic en-
hancer role of the polymorphism in the case of cis pres-
entation. Moreover, the clinical data from both families
suggest a trend towards an earlier age at diagnosis of
MTC in the RET-G691S/S891A carriers irrespectively of
the cis or trans presentation of the RET-S891A mutation
and the RET-G691S polymorphism (Additional file 1:
Figure S1B). Therefore, it is conceivable to hypothesize
that the RET-G691S polymorphism may act as genetic
modifier also in the case of trans presentation with RET-
S891A mutation. However, further studies are necessary
to demonstrate that RET-G691S polymorphism may en-
hance the oncogenic activity of RET-S891A, or of other
RET mutants, also in trans.
Moreover, clinical data from Family 2 indicate that two
out of three RET-G691/S891A patients had elevated nor-
metanephrine levels, suggesting that the full expression
of MEN2A phenotype could be related to the associ-
ation with this non synonymous polymporphism, espe-
cially in the case of cis presentation with RET-S891A
mutation.
Conclusion
In conclusion, RET-G691S polymorphism has been shown
in vitro to enhance the oncogenic potential of the RET-
S891A mutation and in vivo to modify the clinical expres-
sion of the disease.
The genetic analysis of RET-G691S in other series with
RET-S891A or other RET mutations is desirable to con-
firm the role of this polymorphism in the modulation of
the phenotype, particularly in intermediate risk forms.
If confirmed, present data suggest that the evaluation of
RET-G691S in RET carriers should be always recommendedin order to select the more appropriate clinical and follow-
up management.
Additional file
Additional file 1: Figure S1. Age distribution of RET-S891A MTC
patients harboring or not the polymorphism. The age at the diagnosis
(age at DX) and the median are reported for MTC patient from Family 1
(A) and for MTC patient from both families analyzed together (B). The
comparison between groups, performed by Wilcoxon rank sum test,
results not statistically significant. The two RET-G691S/S891A MTC patients
of family 2 displaying elevated urinary normetanephrine levels are
marked (red asterisks).
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